Integra LifeSciences (NSDQ:IART) said today that its shareholders have approved a 2-for-1 stock split, alongside an increase from 60 million to 240 million shares of stock.
Shares are expected to be distributed by January 3, with the adjusted stock price expected to be reflected on the market the next day.
The split, which will put a second share in the hands of every shareholder, went into effect yesterday according to an SEC filing.
In January, Integra LifeSceinces said it won expanded FDA approval for its Omnigraft dermal regeneration matrix, now indicated to treat diabetic foot ulcers.
The device, made of silicone, cow collagen and shark cartilage, is placed over the ulcer to provide a new environment for the skin and tissue to regenerate and heal the wound, according to the Plainsboro, N.J.-based company.
The post Integra LifeSciences shareholders approve 2-for-1 reverse stock split appeared first on MassDevice.
